Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity
Name
s41590-024-01925-7.pdf
Description
Published version
Size
13.01 MB
Format
Adobe PDF
Checksum (MD5)
563ba1b53f7e69db347f0cf020cc034c
Author(s) • • • • • • • • •
Santollani, Luciano
Maiorino, Laura
Zhang, Yiming J
Palmeri, Joseph R
Stinson, Jordan A
Duhamel, Lauren R
Qureshi, Kashif
Suggs, Jack R
Porth, Owen T
Pinney, William
Date Issued
August 7, 2024
Journal
Nature Immunology
Publisher
Springer Science and Business Media LLC
Citation
Santollani, L., Maiorino, L., Zhang, Y.J. et al. Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity. Nat Immunol 25, 1820–1829
Version
Final published version
Abstract
Systemically administered cytokines are potent immunotherapeutics but can cause severe dose-limiting toxicities. To overcome this challenge, cytokines have been engineered for intratumoral retention after local delivery. However, despite inducing regression of treated lesions, tumor-localized cytokines often elicit only modest responses at distal untreated tumors. In the present study, we report a localized cytokine therapy that safely elicits systemic antitumor immunity by targeting the ubiquitous leukocyte receptor CD45. CD45-targeted immunocytokines have lower internalization rates relative to wild-type counterparts, leading to sustained downstream cis and trans signaling between lymphocytes. A single intratumoral dose of αCD45-interleukin (IL)-12 followed by a single dose of αCD45-IL-15 eradicated treated tumors and untreated distal lesions in multiple syngeneic mouse tumor models without toxicity. Mechanistically, CD45-targeted cytokines reprogrammed tumor-specific CD8+ T cells in the tumor-draining lymph nodes to have an antiviral transcriptional signature. CD45 anchoring represents a broad platform for protein retention by host immune cells for use in immunotherapy.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Koch Institute for Integrative Cancer Research at MIT
Massachusetts Institute of Technology. Department of Biological Engineering
Ragon Institute of MGH, MIT and Harvard
Massachusetts Institute of Technology. Department of Materials Science and Engineering
Terms of Use
Creative Commons Attribution
Persistent DSpace Link
DOI of Published Version
10.1038/s41590-024-01925-7